The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
MAPPYACTS (NCT02613962) is an international prospective precision medicine trial aiming to define tumor molecular profiles in pediatric patients with recurrent/refractory malignancies in order to suggest the most adapted salvage treatment. From February 2016 to July 2020, 787 patients were included in France, Italy, Ireland, and Spain. At least one genetic alteration leading to a targeted treatment suggestion was identified in 436 patients (69%) with successful sequencing; 10% of these alterations were considered “ready for routine use.” Of 356 patients with follow-up beyond 12 months, 107 (30%) received one or more matched targeted therapies—56% of them within early clinical trials—mainly in the AcSé-ESMART platform trial (NCT02813135). Overall, matched treatment resulted in a 17% objective response rate, and of those patients with ready for routine use alterations, it was 38%. In patients with extracerebral tumors, 76% of actionable alterations detected in tumor tissue were also identified in circulating cell-free DNA (cfDNA). Significance: MAPPYACTS underlines the feasibility of molecular profiling at cancer recurrence in children on a multicenter, international level and demonstrates benefit for patients with selected key drivers. The use of cfDNA deserves validation in prospective studies. Our study highlights the need for innovative therapeutic proof-of-concept trials that address the underlying cancer complexity. This article is highlighted in the In This Issue feature, p. 1171
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
The landscape of genomic alterations across childhood cancers
ICGC PedBrain-Seq Project, Gröbner, S. N., ICGC MMML-Seq Project, Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A., Johann, P. D., Balasubramanian, G. P., et al. (2018) · Nature · doi:10.1038/nature25480 · Cited by 1,572 · cited 1×
“Furthermore, our data may suggest that TMB may be higher at disease recurrence than in newly diagnosed patients, as reported previously in a lower number of patients (39).”
ResultSelf-citationDurable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML
DiNardo, C. D., Stein, E. M., de Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., Swords, R., Collins, R. H., Mannis, G. N., Pollyea, D. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716984 · Cited by 1,454
Germline Mutations in Predisposition Genes in Pediatric Cancer
Zhang, J., Walsh, M. F., Wu, G., Edmonson, M. N., Gruber, T. A., Easton, J., Hedges, D., Ma, X., Zhou, X., Yergeau, D. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1508054 · Cited by 1,345 · cited 1×
“Germline findings were reported in cancer predisposition genes, as published by Zhang and colleagues (38).”
BackgroundLe Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137 · cited 8×
“Most of them are identical to our highest-level alterations, albeit we have not considered for example HRAS/KRAS and ALK mutations because of the limited clinical activity of MEK and ALK inhibitors in patients with these alterations (35–38).”
BackgroundSelf-citationChildhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study
Gatta, G., Botta, L., Rossi, S., Aareleid, T., Bielska-Lasota, M., Clavel, J., Dimitrova, N., Jakab, Z., Kaatsch, P., Lacour, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70548-5 · Cited by 1,075 · cited 6×
“Ten cases were found with mutations in NTRK (3), SMO (3), ALK (3), and NRAS (1) that may be associated with treatment resistance; all except one had previously received the specific NTRK, SMO, ALK, or BRAF/MEK inhibitors, respectively, and benefited from the procedure at treatment failure.”
BackgroundInfluentialHong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30856-3 · Cited by 1,028
Self-citationMassard, C., Michiels, S., Ferté, C., Le Deley, M.-C., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E., Rosellini, S., Ammari, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1396 · Cited by 783 · cited 5×
“Libraries were prepared with TruSeq Stranded mRNA kit, PolyA mRNA capture with oligo dT beads 1 mg total RNA, fragmentation to approximately 400 bp, cDNA double-strand synthesis, and ligation of adaptors, library amplification, and sequencing (2, 19).”
BackgroundMethodSelf-citationFangusaro, J., Onar-Thomas, A., Young Poussaint, T., Wu, S., Ligon, A. H., Lindeman, N., Banerjee, A., Packer, R. J., Kilburn, L. B., Goldman, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30277-3 · Cited by 507 · cited 1×
“(10), NTRK1/2/3 (9), ROS1 (2), COL1A1/PDGFB (1), and RET (1), pathogenic mutations in BRAF (4), NF1 (2), and IDH1 (1), or mutation or deletion in PTCH1 (4) in selected tumor types (Table 1).”
BackgroundParsons, D. W., Roy, A., Yang, Y., Wang, T., Scollon, S., Bergstrom, K., Kerstein, R. A., Gutierrez, S., Petersen, A. K., Bavle, A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5699 · Cited by 491
Robinson, G. W., Orr, B. A., Wu, G., Gururangan, S., Lin, T., Qaddoumi, I., Packer, R. J., Goldman, S., Prados, M. D., Desjardins, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.1591 · Cited by 448
Mossé, Y. P., Voss, S. D., Lim, M. S., Rolland, D., Minard, C. G., Fox, E., Adamson, P., Wilner, K., Blaney, S. M., & Weigel, B. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.4830 · Cited by 413
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
Mody, R. J., Wu, Y.-M., Lonigro, R. J., Cao, X., Roychowdhury, S., Vats, P., Frank, K. M., Prensner, J. R., Asangani, I., Palanisamy, N., et al. (2015) · JAMA · doi:10.1001/jama.2015.10080 · Cited by 411
Wong, M., Mayoh, C., Lau, L. M. S., Khuong-Quang, D.-A., Pinese, M., Kumar, A., Barahona, P., Wilkie, E. E., Sullivan, P., Bowen-James, R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1072-4 · Cited by 393 · cited 2×
“MAY 2022 CANCER DISCOVERY | 1277 Although theoretically it would be preferable to treat patients based on the sequencing results of the current relapse, avoiding further temporal tumor evolution, this pragmatic approach was deemed suitable for most patients and, as done in most other programs, with advanced molecular…”
BackgroundPark, J. R., Bagatell, R., Cohn, S. L., Pearson, A. D., Villablanca, J. G., Berthold, F., Burchill, S., Boubaker, A., McHugh, K., Nuchtern, J. G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.0177 · Cited by 365
Self-citationWorst, B. C., van Tilburg, C. M., Balasubramanian, G. P., Fiesel, P., Witt, R., Freitag, A., Boudalil, M., Previti, C., Wolf, S., Schmidt, S., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.009 · Cited by 330 · cited 2×
“These alterations included gene amplifications, fusion, or activating mutations in MYCN/MYC (43), KRAS/NRAS/HRAS (42), FGFR1/2/3/4 (27), PIK3CA/PIK3R1/2 (23), ALK (15), and deletions or deleterious mutations in TP53 (215), CDK2NA/B (157), NF1 (33), SMARCA4/SMARCB1 (27), PTEN (25), and RB1 (11; Table 1).”
BackgroundStockley, T. L., Oza, A. M., Berman, H. K., Leighl, N. B., Knox, J. J., Shepherd, F. A., Chen, E. X., Krzyzanowska, M. K., Dhani, N., Joshua, A. M., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0364-2 · Cited by 276 · cited 5×
“Ten cases were found with mutations in NTRK (3), SMO (3), ALK (3), and NRAS (1) that may be associated with treatment resistance; all except one had previously received the specific NTRK, SMO, ALK, or BRAF/MEK inhibitors, respectively, and benefited from the procedure at treatment failure.”
BackgroundInfluentialLeijen, S., van Geel, R. M. J. M., Pavlick, A. C., Tibes, R., Rosen, L., Razak, A. R. A., Lam, R., Demuth, T., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5991 · Cited by 264 · cited 5×
“These alterations included gene amplifications, fusion, or activating mutations in MYCN/MYC (43), KRAS/NRAS/HRAS (42), FGFR1/2/3/4 (27), PIK3CA/PIK3R1/2 (23), ALK (15), and deletions or deleterious mutations in TP53 (215), CDK2NA/B (157), NF1 (33), SMARCA4/SMARCB1 (27), PTEN (25), and RB1 (11; Table 1).”
BackgroundInfluentialvan Tilburg, C. M., Pfaff, E., Pajtler, K. W., Langenberg, K. P. S., Fiesel, P., Jones, B. C., Balasubramanian, G. P., Stark, S., Johann, P. D., Blattner-Johnson, M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0094 · Cited by 262 · cited 3×
“MAY 2022 CANCER DISCOVERY | 1277 Although theoretically it would be preferable to treat patients based on the sequencing results of the current relapse, avoiding further temporal tumor evolution, this pragmatic approach was deemed suitable for most patients and, as done in most other programs, with advanced molecular…”
BackgroundResultHargrave, D. R., Bouffet, E., Tabori, U., Broniscer, A., Cohen, K. J., Hansford, J. R., Geoerger, B., Hingorani, P., Dunkel, I. J., Russo, M. W., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2177 · Cited by 214
Self-citationHarris, M. H., DuBois, S. G., Glade Bender, J. L., Kim, A., Crompton, B. D., Parker, E., Dumont, I. P., Hong, A. L., Guo, D., Church, A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5689 · Cited by 206
Trédan, O., Wang, Q., Pissaloux, D., Cassier, P., de la Fouchardière, A., Fayette, J., Desseigne, F., Ray-Coquard, I., de la Fouchardière, C., Frappaz, D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz080 · Cited by 189
Kieran, M. W., Chisholm, J., Casanova, M., Brandes, A. A., Aerts, I., Bouffet, E., Bailey, S., Leary, S., MacDonald, T. J., Mechinaud, F., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox109 · Cited by 175
Self-citationHarttrampf, A. C., Lacroix, L., Deloger, M., Deschamps, F., Puget, S., Auger, N., Vielh, P. R., Varlet, P., Balogh, Z., Abbou, S. D., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0381 · Cited by 157 · cited 4×
“8) or in-house pipelines consisting in alignment of sequencing reads on the hg19 human genome (Build37), determination of structural variants, CNAs, and variant detection, as well as determination of their functional impact (19, 41).”
BackgroundMethodResultSelf-citationNavarrete‐Dechent, C., Mori, S., Barker, C. A., Dickson, M. A., & Nehal, K. S. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2018.4940 · Cited by 151
Chicard, M., Colmet-Daage, L., Clement, N., Danzon, A., Bohec, M., Bernard, V., Baulande, S., Bellini, A., Deveau, P., Pierron, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1586 · Cited by 148 · cited 3×
“For patients with non-CNS solid tumors, cfDNA extracted from plasma was quantified using Qubit HS DNA assays for WES at 100× (41).”
BackgroundMethodSelf-citationEscudero, L., Llort, A., Arias, A., Diaz-Navarro, A., Martínez-Ricarte, F., Rubio-Perez, C., Mayor, R., Caratù, G., Martínez-Sáez, E., Vázquez-Méndez, É., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19175-0 · Cited by 124 · cited 3×
“Furthermore, recent reports demonstrate the feasibility of cfDNA extracted from CSF for patients with CNS malignancies (42).”
BackgroundChicard, M., Boyault, S., Colmet Daage, L., Richer, W., Gentien, D., Pierron, G., Lapouble, E., Bellini, A., Clement, N., Iacono, I., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0500 · Cited by 113 · cited 1×
“Higher cfDNA quantities, and a higher content of ctDNA in cfDNA, were observed in patients with neuroblastoma compared with other disease types, confirming previous studies of the feasibility of ctDNA studies in these patients with different analytical techniques such as low-coverage whole-genome sequencing, WES, or d…”
ResultSelf-citationPrecision medicine in pediatric oncology: Lessons learned and next steps
Mody, R. J., Prensner, J. R., Everett, J. N., Parsons, D. W., & Chinnaiyan, A. M. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26288 · Cited by 104
Drilon, A. E. D. C., DuBois, S. G., Farago, A. F., Geoerger, B., Grilley‐Olson, J. E., Hong, D. S., Sohal, D. P. S., van Tilburg, C. M., Ziegler, D. S., Ku, N. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2006 · Cited by 79
Self-citationMolecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers
Khater, F., Vairy, S., Langlois, S., Dumoucel, S., Sontag, T., St-Onge, P., Bittencourt, H. N. D. S., Soglio, D. B. D., Champagne, J., Duval, M., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2906 · Cited by 70
Pincez, T., Clément, N., Lapouble, E., Pierron, G., Kamal, M. T., Bièche, I., Bernard, V., Fréneaux, P., Michon, J. M., Orbach, D. H., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26365 · Cited by 67 · cited 1×
“Consistent with our preliminary monocentric experiences (19, 20) and other reports (19, 21–26), 69% of patients in MAPPYACTS had one or more genomic alterations in their tumor that we considered “potentially actionable” through targeted agents.”
ResultSelf-citationRobinson, G. W., Gajjar, A. J., Gauvain, K., Basu, E. M., Macy, M. E., Maese, L. D., Sabnis, A. J., Foster, J. H., Shusterman, S., Yoon, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.10009 · Cited by 62 · cited 1×
“Procedure-related adverse events were grade 1 (17), grade 2 (31), grade 3 (12), and grade 4 (7) in the 833 cases.”
BackgroundPasqualini, C., Rubino, J., Brard, C., Cassard, L., André, N., Rondof, W., Scoazec, J., Marchais, A., Nebchi, S., Boselli, L., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.032 · Cited by 59 · cited 1×
“Somatic coding mutations were filtered according to their enrichment in the tumor samples compared with the paired normal samples as reported previously (30).”
ResultSelf-citationOrtiz, M. V., Gerdemann, U., Raju, S. G., Henry, D., Smith, S., Rothenberg, S. M., Cox, M. C., Proust, S., Bender, J. G., Frazier, A. L., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00401 · Cited by 44
Geoerger, B., Schulte, J. H., Zwaan, C. M., Casanova, M., Fischer, M., Moreno, L., Trahair, T. N., Jiménez, I., Kang, H. J., Pappo, A. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.10005 · Cited by 37
Self-citationBautista, F., Paolettí, X., Rubino, J., Brard, C., Rezaï, K., Nebchi, S., André, N., Aerts, I., Carli, E. D., van Eijkelenburg, N., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01152 · Cited by 35 · cited 1×
“Procedure-related adverse events were grade 1 (17), grade 2 (31), grade 3 (12), and grade 4 (7) in the 833 cases.”
BackgroundSelf-citationMorscher, R. J., Brard, C., Berlanga, P., Marshall, L. V., André, N., Rubino, J., Aerts, I., Carli, É. D., Corradini, N., Nebchi, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.010 · Cited by 34
Self-citationCohen, J. W., Akshintala, S., Kane, E., Gnanapragasam, H. P., Widemann, B. C., Steinberg, S. M., & Shah, N. N. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0615 · Cited by 27 · cited 1×
“Overall ORR of patients in MAPPYACTS was 17% and 14% for lower-level evidence treatments, thus superior to the reported 4% ORR observed in pediatric phase I/II chemotherapy trials (27) and similar to the outcome in the targeted therapies era (28).”
Result
Cited by
Combined low-pass whole genome and targeted sequencing in liquid biopsies for pediatric solid tumors
Christodoulou, E., Yellapantula, V., O’Halloran, K., Xu, L., Berry, J. L., Cotter, J. A., Zdanowicz, A., Mascarenhas, L., Amatruda, J. F., Ostrow, D., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00357-0 · Cited by 55
Audinot, B., Drubay, D., Gaspar, N., Mohr, A., Cordero, C., Marec-Bérard, P., Lervat, C., Piperno-Neumann, S., Jimenez, M., Mansuy, L., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.12.006 · Cited by 38
Self-citation
Metadata
- Authors
- Berlanga, P., Pierron, G., Lacroix, L., Chicard, M., Adam de Beaumais, T., Marchais, A., Harttrampf, A. C., Iddir, Y., Larive, A., Soriano Fernandez, A., Hezam, I., Chevassus, C., Bernard, V., Cotteret, S., Scoazec, J.-Y., Gauthier, A., Abbou, S., Corradini, N., André, N., Aerts, I., Thebaud, E., Casanova, M., Owens, C., Hladun-Alvaro, R., Michiels, S., Delattre, O., Vassal, G., Schleiermacher, G., & Geoerger, B.
- Venue
- Cancer Discovery
- Published
- 2022-03-16
- Volume
- 12
- Issue
- 5
- Pages
- 1266-1281
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W4220935578
- Cited by
- 165
- References
- 41
- FWCI
- 11.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.